09 January 2026 : Clinical Research
Baseline Tumor Biology Predicts Survival After Recurrence in Gastric Cancer: Impact of LVI, PNI, and HER2 Status
Gözde Ağdaş
ABCDE 1*, Mehmet Salim Demir AF 1
DOI: 10.12659/MSM.951829
Med Sci Monit 2026; 32:e951829
Table 2 Pathological findings and treatment characteristics, including lymph node data and recurrence patterns.
| Min–Max | Median | Mean±SD/n-% | |||
|---|---|---|---|---|---|
| LND | I | 15 | 21.4% | ||
| II | 55 | 78.6% | |||
| Retrived LNs | 5.0–53.0 | 24.5 | 25.9±12.5 | ||
| Metastatic LNs | 0.0–32.0 | 4.0 | 7.6±7.7 | ||
| LVI | 52 | 74.3% | |||
| PNI | 48 | 68.6% | |||
| Adjuvant CT | 47 | 67.1% | |||
| First-line CT | 59 | 84.3% | |||
| Second-line CT | 28 | 40.0% | |||
| Third-line CT | 11 | 15.7% | |||
| Adjuvant CRT | 24 | 34.3% | |||
| Recurrence | 70 | 100.0% | |||
| Recurrence site | Liver | 30 | 42.9% | ||
| Peritoneum | 25 | 35.7% | |||
| Lung | 6 | 8.6% | |||
| LAP | 4 | 5.7% | |||
| Locally | 3 | 4.3% | |||
| Bone | 2 | 2.9% | |||
| Exitus | 58 | 82.9% | |||
| Follw-up time (months) | 3.2–135.8 | 26.7 | 32.3±23.2 | ||
| LND – lymph node dissection; LNs – lymph nodes; LVI – lymphovascular nnvasion; PNI – perineural invasion; CT – chemotherapy; CRT – chemoradiotherapy. | |||||